Fig. 1.

GOLM1-deficient mice are more susceptible to AOM/DSS-induced colon tumorigenesis. a GOLM1 expression in human colorectal cancer (CRC) tissues compared with that in normal tissues using expression data from the TCGA database (***P < 0.001; unpaired, two-tailed Student’s t test). b Curves for overall survival are shown between high and low expression of GOLM1 in CRC samples based on the TCGA database. c Curves for disease-specific survival are shown between high and low expression of GOLM1 in CRC samples based on the TCGA database. d Human CRC and adjacent normal tissues we collected were extracted and immunoblotted (n = 10). e Representative images of colon tumors obtained from AOM/DSS-treated mice. f The average ratio of colon weight/body weight in AOM/DSS-treated mice (each symbol in each column represents an individual mouse, n = 8; the data are represented as the means ± SEM; ***P < 0.01; unpaired, two-tailed Student’s t test). g Representative images of the spleen obtained from AOM/DSS-treated mice. h Representative Hematoxylin and Eosin (H&E) staining of mouse spleen sections obtained from AOM/DSS-treated mice. Scale bars, 1000 μm. i Relative mRNA expression levels of inflammatory mediators in the distal colon of AOM/DSS-treated mice determined by quantitative reverse transcription PCR (qRT-PCR). Relative expression reflects the fold change calculated by comparing with the average expression levels in untreated WT mice (the data are represented as the means ± SEM, n = 8; ***P < 0.001, *P < 0.05; unpaired, two-tailed Student’s t test). j Representative H&E staining of mouse colon sections obtained from AOM/DSS-treated mice. Upper scale bars, 500 μm; lower scale bars, 50 μm. k Percentages of mice with dysplasia at 70 days after AOM injection administration